Clinical Trials

The purpose of this study is to determine whether eculizumab long-term use is safe and effective in patients with relapsing neuromyelitis optica.

To compare the efficacy of MEDI-551 versus placebo in reducing the risk of an NMO/NMOSD attack in subjects with NMO/NMOSD.

The purpose of this study is to assess the effectiveness and safety of eculizumab treatment as compared to a placebo in patients with relapsing neuromyelitis optica, using a time to first relapse study design.

The primary objective of the study is to assess the efficacy and safety of eculizumab treatment as compared to placebo in relapsing NMO patients using a time to first relapse study design.

The purpose of this study is to determine whether eculizumab long-term use is safe and effective in patients with relapsing NMO.

The purpose of this study is to collect information on the natural history of neuromyelitis optica spectrum disorder (NMOSD) in pediatric AQP4-IgG seropositive patients in the Mayo Clinic neuromyelitis optica spectrum disorder (NMOSD) Pediatric Repository.

The primary purpose of this study is to evaluate the effectiveness and safety of Ravulizumab for the treatment of adult participants with Neuromyelitis Optica Spectrum Disorder (NMOSD).

Neuromyelitis optica (NMO) is an inflammatory disease of the central nervous system that is associated with autoantibodies to aquaporin-4. Treatment options for prevention of clinical relapses of NMO include immunosuppressive medications. Plasma exchange (PLEX) is commonly used as a rescue therapy for NMO relapses but ongoing, regular PLEX procedures (maintenance PLEX) is sometimes used to prevent relapses. This observational registry will record feasibility, tolerability, safety, and preliminary efficacy data regarding maintenance PLEX for NMO.

The primary objective is of this protocol to create a database of NMO patient information that can be queried to address specific scientific questions.  The first series of questions will focus on the clinical characteristics and course of the disease.  For example, sex ratio, ethnicity, and age of onset will be described for NMOSD as a whole and amongst the different diagnostic subcategories.  A main question of whether NMO-IgG seropositive patients differ with respect to disease activity compared with seronegative patients and exploratory multivariable analyses of the natural history will be conducted

Aims, purpose, or objectives:

1. To describe the clinical features along with treatment outcomes of a cohort of patients with a diagnosis of NMOSD after the latest revised criteria in 2015 by International Panel for Neuromyelitis Optica Diagnosis (IPND)
2. To described the long term outcomes of a cohort of patients with a diagnosis of NMOSD
3. To identify demographic, clinical and radiologic factors associated with long terms outcomes of NMOSD
4. To determine if patients who are diagnosed with the revised 2015 IPND criteria, in particular those who do not satisfy previous criteria, are ultimately diagnosed with ...

The purpose of this study is to establish a repository consisting of clinical information, radiological data, serum, peripheral blood lymphocytes, plasma, cerebrospinal fluid (CSF), urine, stool, DNA and tissue specimens collected from patients who have central nervous system (CNS)  inflammatory diseases. 

The aim is to establish a repository consisting of clinical information, radiological data, serum, peripheral blood lymphocytes, plasma, cerebrospinal fluid (CSF), and tissue specimens collected prospectively from patients with CNS diseases and controls.